<DOC>
	<DOCNO>NCT00868595</DOCNO>
	<brief_summary>This Phase I , non-randomized , multiple-dose , 3+3 dose-escalation study safety , pharmacokinetics , biomarkers , preliminary efficacy patient-reported outcome therapeutic vaccine , BPX-101 ( formerly BP-GMAX-CD1 ) , plus activate agent , AP1903 , patient castrate resistant prostate cancer .</brief_summary>
	<brief_title>MTD Study Vaccine BP-GMAX-CD1 Plus AP1903 Treat Castrate Resistant Prostate Cancer</brief_title>
	<detailed_description>Patients screen within 6 week prior Week 1 . A total 3 cohort , consist 3 6 patient , plan receive five eight intradermal ( ID ) injection total 1 mL 1.6mL BPX-101 3 dos level initial 6 dos .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males ≥ 18 year age 2 . Histological diagnosis adenocarcinoma prostate 3 . Documented evidence distant metastasis disease 4 . No 1 prior chemotherapeutic , biologic combination treatment regimen ( include vitamin D analogue ) CRPC . If previously treat , patient must recover toxicity prior entry study . 5 . Patients must current historical evidence disease progression concomitant surgical ( orchiectomy ) medical castration ( LHRH analogue ) ; antiandrogen withdrawal ( 4 week flutamide 6 week nilutamide bicalutamide ) necessary patient antiandrogens duration response antiandrogens &gt; 3months ; 6 . Testosterone &lt; 50 ng/dL achieve via medical surgical castration . Patients receive medical castration therapy must continue therapy throughout study . 7 . Adequate hematologic , renal liver function : 8 . Negative serology test human immunodeficiency virus ( HIV1 2 ) , human Tcell lymphotropic virus ( HTLV1 ) , hepatitis B surface antigen ( HBsAg ) hepatitis C ( HCV ) 9 . Karnofsky Performance Score ( KPS ) ≥ 70 % 10 . Life expectancy &gt; 6 month 11 . Written inform consent obtain prior initiation study procedures 1 . The presence brain metastasis , pleural effusion ascites 2 . Pathologic longbone fracture , imminent pathologic longbone fracture ( cortical erosion radiography &gt; 50 % ) , spinal cord compression 3 . A history stage III great cancer , exclude prostate cancer . Basal squamous cell skin cancer must adequately treated patient must diseasefree time registration . Patients history stage I II cancer must adequately treat diseasefree 3 year time registration . 4 . More 1 prior chemotherapy , biologic combination treatment regimen ( include vitamin D analogue ) CRPC 5 . Any treatment radiopharmaceutical , e.g . Strontium89 Samarium153 6 . Ketoconazole antiandrogens ( flutamide , nilutamide , bicalutamide ) within 2 week prior registration . Patients demonstrate antiandrogen withdrawal response , define &gt; 25 % drop PSA within 4 week ( flutamide ) 6 week ( nilutamide , bicalutamide ) stop nonsteroidal antiandrogen , eligible PSA rise nadir observe antiandrogen withdrawal . 7 . Initiation bisphosphonate therapy within 28 day prior registration . Patients take bisphosphonates dose regimen alter unless medically warrant . 8 . A requirement systemic steroid immunosuppressive therapy reason . 9 . Treatment follow medication intervention &lt; 28 day prior Screening 10 . Treatment investigational vaccine within 2 year prior Screening , treatment investigational product within 28 day prior Screening 11 . Any antibiotic therapy infection within 1 week prior Screening , include unexplained fever ( temperature ≥ 100.5F 38.1C ) 12 . History autoimmune disease 13 . Serious ongoing chronic acute illness 14 . Any medical intervention condition , opinion Principal Investigator and/or Bellicum Medical Monitor , could compromise adherence study requirement Other Criteria Apply however list</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>